Beam Therapeutics

CAMBRIDGE, MA · Founded 2017 · CIK 0001745999 · Biotech

Base editing therapies for genetic medicine

beamtx.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$180M
2 Form D · Mar 2019
91 months since last filing
Contracts
—
No federal contracts on record
Patents
40
7 granted · 33 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$44,999,981
Private capital raisedForm D · SEC$135,000,002
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1270NEUROEPIGENIX, LLC——
1271Third Harmonic Bio——
1272BridgeBio Oncology Therapeutics——
1273Beam Therapeutics—$180M
1274SYNSPIRA THERAPEUTICS, INC.——
1275NANOTHERAPEUTICS, INC.——
1276FIBROPLATE INC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • KRISTINA BUROWDirector
  • JOHN EVANSDirector · Executive Officer
  • MARK FISHMANDirector
  • CAROLE HODirector
  • STEPHEN KNIGHTDirector
  • ROBERT NELSENDirector
  • ROBERT NELSONDirector
  • MICHAEL YIDirector
  • FENG ZHANGDirector

Patents

USPTO · 7 granted of 40
  • Prime Editing Of Single Base Mutations In Sickle Cell Diseaseapplication
  • Compositions And Methods For Altering Complement Activationapplication
  • Compositions And Methods For Treating ALPHA-1 Antitrypsin Deficiencyapplication
  • Methods And Compositions For Treating ALPHA-1 Antitrypsin Deficiencyapplication
  • Nanomaterials Comprising Triolsapplication
  • Nucleobase Editors Having Reduced Non-target Deamination And Assays For Characterizing Nucleobase Editorsapplication
  • Compositions And Methods For Base Editing A Phenylalanine Hydroxylase Polynucleotideapplication
  • Immunosuppressant-resistant Modified Allogeneic Modified Immune Cells And Methods For Use Thereofapplication
  • Compositions And Methods For Altering A Nucleobase In A Lipoprotein(a) Polynucleotideapplication
  • Ionizable Lipids With Linear Head Groupsapplication
  • Compositions And Methods For Delivering A Nucleobase Editing Systemapplication
  • Ionizable Lipids With Branched Head Groupsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.